|Mr. Andrew Rackear J.D.||Chief Exec. Officer and Sec.||139.16k||N/A||63|
|Mr. Richard L. Feinstein CPA||Chief Financial Officer and VP of Fin.||159.51k||N/A||74|
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. The companys marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular wet age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohns disease. Enzon Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Cranford, New Jersey.
Enzon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.